Computational Method Offers Significant Boost in Finding New Cancer Targets
Article Jul 13, 2016
A team from Massachusetts Institute of Technology and ARIAD Pharmaceuticals, USA, have developed a computational methodology to predict significant overlap between variants in inherited disease and existing cancer genetic databases. So far they have added new cancer associated genes, substantially expanded the therapeutically actionable population of patients harbouring activating mutations in ACVR1, and identified the first evidence of significant mutations in CDK4 in lung cancer and in SOS1 in melanoma.
Current identification of driver cancer genes from cohort studies is limited by statistical resolution. Published last month in PLOS Genetics (Zhao & Pritchard (2016) Inherited Disease Genetics Improves the Identification of Cancer-Associated Genes.PLoS Genet 12(6): e1006081.doi:10.1371/journal.pgen.1006081), this new study demonstrates how anyone with a database of amino acid variants from diverse methodologies (e.g., mutagenesis screens or biochemical analyses) can investigate cancer associations further and add statistical rigour to findings.
The team merged data from the pathogenic entries in the UniProt HUMSAVAR database and the entire set of tumour exomes featured on the cBioPortal and applied a computational model with a match score (per gene per study) to make comparisons between datasets with an additional boot strap approach to assess the confidence in the score, by deriving a signal-to-noise ratio.
This paper demonstrates how intelligent new methods such as this can boost development of new cancer therapies by making orphan diseases a little more common and identifying larger unmet medical needs.
Justin Pritchard commented “Of direct and timely biological interest is the first identification of ACVR1 mutations in adult cancers (specifically, uterine cancers). Kinase activating ACVR1 mutations are responsible for the extraordinarily rare and devastating Fibrodysplasia Ossificans Progressiva (FOP) also known as “stone man syndrome” for the manner in which it locks people in an ectopic skeleton. Last year activating mutations in the same gene were found in extraordinarily rare pediatric gliomas and reported in 4 simultaneous papers in Nature Genetics and profiled in Cancer Research.”
The Glycome and CancerArticle
The surfaces of cancer cells frequently express different types of glycoproteins, and because healthy cells don’t express these molecules (or do so at a much lower level), there has been significant interest in them as potential anticancer targets. Recent advances suggest we are about to see a resurgence in cancer glycomics.READ MORE
Cisplatin Efficacy: The Importance of Measuring Uptake in Cancer CellsArticle
Although cisplatin is clinically proven to combat numerous human cancers – bladder, head and neck, lung, ovarian, testicular – resistance to treatment remains a key challenge, and cisplatin patients can often relapse. Having the ability to determine the cellular uptake of cisplatin is key to developing novel strategies to increase tumor cell sensitivity to cisplatin.READ MORE
Case Study: Improve your lab’s efficiency and data compliance with a chromatography data systemArticle
In this Case Study, Peter Zipfell of Thermo Fisher Scientific explains how Broughton Laboratories, an analytical laboratory that supports method development and validation projects across pharma, implemented and upgraded a chromatography data system (CDS), increasing lab efficiency and improving data verification processes for overall time savings.READ MORE